Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-28T12:10:06.901Z Has data issue: false hasContentIssue false
  • English
  • Français

The future of masking

Published online by Cambridge University Press:  28 January 2021

Leonard A. Mermel Open the ORCID record for Leonard A. Mermel [Opens in a new window]
Leonard A. Mermel*
Affiliation:
Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island Division of Infectious Diseases, Rhode Island Hospital, Providence, Rhode Island Department of Epidemiology and Infection Control, Rhode Island Hospital, Providence, Rhode Island
*
Author for correspondence: Dr Leonard Mermel, E-mail: [email protected]
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Letter to the Editor
Information
Infection Control & Hospital Epidemiology , Volume 43 , Issue 3 , March 2022 , pp. 403 - 404
Check for updates
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

To the Editor—The 2 mRNA vaccines now administered in the United States offer >90% protection against symptomatic coronavirus disease 2019 (COVID-19) infection based on published data. How long the protection lasts beyond a few months is uncertain at the present time. There is one report of COVID-19 reinfection in an otherwise healthy adult 6 months after the initial infection despite production of neutralizing antibodies after the first infection.Reference Selhorst, Van Ierssel and Michiels1 This individual apparently spread COVID-19 while reinfected, likely reflecting viral replication in the nares in the absence of neutralizing antibodies at that site (ie, lack of mucosal immunity). Widespread vaccination will inevitably reduce the COVID-19 reproductive number, thereby changing the transmission dynamics in many parts of the world. However, infection among those unvaccinated and reinfection in unvaccinated and vaccinated individuals remains an ongoing concern.

Universal masking, along with other public health measures, slows COVID-19 transmission.Reference Leung, Chu and Shiu2,Reference Kwon, Joshi and Lo3 These interventions have also reduced transmission of other respiratory viruses over the last year,Reference Baker, Park, Yang, Vecchi, Metcalf and Grenfell4 thereby reducing associated morbidity and mortality.Reference Chow and Mermel5 The durability of protection against COVID-19 infection after vaccination is unclear, and universal masking is associated with reduced risk of COVID-19 and infection from other respiratory viruses. What will be the role of masking in the future?

Universal masking should continue until COVID-19 herd immunity is reached from natural disease and vaccination. Thereafter, particularly during winter months,Reference Choe, Smit and Mermel6,Reference Park, Lee, Michelow and Choe7 universal masking should continue in congregate settings and other indoor settings where social distancing cannot be maintained and/or the introduction of fresh air introduced into the environment, or filtration of recirculated air, is suboptimal.Reference Somsen, van Rijn, Kooij, Bem and Bonn8 Mask wearing will be particularly important for those individuals at greatest risk of poor outcomes with COVID-19 infection.9 By reducing transmission of respiratory viruses, masking should reduce immune selection pressure in infected individuals, and lower the likelihood that severe acute respiratory coronavirus virus 2 (SARS-CoV-2) will become more transmissible in the future.Reference Kemp, Datir and Collier10 There will be temptation to lower our guard and not follow advice about social distancing and masking after vaccination. However, we must learn from our experience over the past year. Failure to maintain more than a modicum of masking would reflect an inability to learn from the past to improve our lives in the future.

Acknowledgments

Financial support

No financial support was provided relevant to this article.

Conflicts of interest

All authors report no conflicts of interest relevant to this article.

References

Selhorst, P, Van Ierssel, S, Michiels, J, et al. Symptomatic SARS-CoV-2 reinfection of a healthcare worker in a Belgian nosocomial outbreak despite primary neutralizing antibody response. Clin Infect Dis 2020. doi: 10.1093/cid/ciaa1850.Google Scholar
Leung, NHL, Chu, DKW, Shiu, EYC, et al. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med 2020. doi: 10.1038/s41591-020-0843-2.Google ScholarPubMed
Kwon, S, Joshi, AD, Lo, CH, et al. Association of social distancing and masking with risk of COVID-19. medRxiv 2020. doi: 10.1101/2020.11.11.20229500.Google ScholarPubMed
Baker, RE, Park, SW, Yang, W, Vecchi, GA, Metcalf, CJE, Grenfell, BT. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proc Natl Acad Sci 2020;117:30547–30553.Google ScholarPubMed
Chow, EJ, Mermel, LA. Hospital-acquired respiratory viral infections: incidence, morbidity, and mortality in pediatric and adult patients. Open Forum Infect Dis 2017;4(1):ofx006.Google ScholarPubMed
Choe, YJ, Smit, MA, Mermel, LA. Comparison of common respiratory virus peak incidence among varying age groups in Rhode Island, 2012–2016. JAMA Netw Open 2020;3(5):e207041.Google ScholarPubMed
Park, S, Lee, Y, Michelow, IC, Choe, YJ. Global seasonality of human coronaviruses: a systematic review. Open Forum Infect Dis 2020;7(11):ofaa443.Google ScholarPubMed
Somsen, GA, van Rijn, C, Kooij, S, Bem, RA, Bonn, D. Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission. Lancet Respir Med 2020;8:658–659.Google ScholarPubMed
People with certain medical conditions. Centers for Disease Control and Prevention website. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html. Accessed December 21, 2020.Google Scholar
Kemp, SA, Datir, RP, Collier, DA, et al. Recurrent emergence and transmission of a SARS-CoV-2 spike deletion ΔH69/ΔV70. bioRxiv doi: 10.1101/2020.12.14.422555.Google Scholar